[Federal Register Volume 67, Number 168 (Thursday, August 29, 2002)]
[Notices]
[Page 55416]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-22075]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: ``Antiprogestins With 
Partial Agonist Activity

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive license worldwide to practice the invention embodied in: 
U.S. Patent Application Serial No. 60/192,039, filed March 24, 2000, 
now converted into PCT application number PCT/US01/09395 filed March 
23, 2001 entitled, ``Antiprogestins with Partial Agonist Activity'' to 
Dimera Inc., having a place of business in the state of Oregon. The 
field of use may be limited to anti-anginal protection/therapy and 
female reproduction therapies. The United States of America is the 
assignee of the patent rights in this invention.

DATES: Only written comments and/or application for a license, which 
are received by the NIH Office of Technology Transfer on or before 
October 28, 2002 will be considered.

ADDRESSES: Requests for a copy of the patent applications, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Marlene Shinn, Technology Licensing Specialist, 
Office of Technology Transfer, National Institutes of Health, 6011 
Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: 
(301) 496-7056, ext. 285; Facsimile: (301) 402-0220; e-mail: 
[email protected].

SUPPLEMENTARY INFORMATION: This technology relates to the results that 
two derivatives of the potent glucocorticoid dexamethasone show partial 
agonist activity under a variety of conditions. These steroids have 
demonstrated affinities for the cell free progesterone receptor that 
are consistent with their whole cell action arising under conditions 
where other reported partial progestins were inactive. Of these new 
antiprogestins that are described in this invention, both Dex-Mes and 
Dex-ox would be both extremely useful for mechanistic studies in tissue 
culture systems. Dex-ox is chemically unreactive, while both exhibit 
considerable amounts of agonist activity under certain circumstances 
and are partial agonist for glucocorticoid receptors.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless, within 60 days 
from the date of this published Notice, NIH receives written evidence 
and argument that establishes that the grant of the license would not 
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    Properly filed competing applications for a license filed in 
response to this notice will be treated as objections to the 
contemplated license. Comments and objections submitted in response to 
this notice will not be made available for public inspection, and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: August 22, 2002.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 02-22075 Filed 8-28-02; 8:45 am]
BILLING CODE 4140-01-P